spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Morphotek 

 HSMN NewsFeed - 10 Jan 2018
Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Sep 2017
Morphotek(R), Inc. Announces an Agreement with Fujirebio Diagnostics, Inc. to Commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab(R)
Biopharmaceuticals Diagnostics Oncology Licensing
 HSMN NewsFeed - 3 Oct 2016
Launch of Carrick Therapeutics Signals New Approach to Cancer Therapies
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 9 Jan 2014
Covidien, Lightstone Ventures, New Enterprise Associates Announce Series A Investment in FIRE1
Devices Venture Capital Personnel
 HSMN NewsFeed - 4 Jan 2013
Inotek Pharmaceuticals Appoints David R. King as Executive Chairman
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 17 Nov 2010
Topaz Pharmaceuticals Names Bob Radie Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jun 2010
Lonnel Coats Appointed President & Chief Executive Officer of Eisai Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jan 2010
The Foundry Announces Completion of Series A Financing for Twelfth Company
Devices Venture Capital
 HSMN NewsFeed - 28 Oct 2009
Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody
Biopharmaceuticals Licensing
 HSMN NewsFeed - 1 Jul 2009
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2009
Marty J. Duvall Joins Abraxis BioScience as Senior Vice President, Global Marketing and International Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Apr 2009
TransMolecular Appoints Robert Radie President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Mar 2009
Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Feb 2009
Selecta Biosciences, Inc. Closes $15.1M Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 28 Jan 2009
The Foundry Announces New Partners and Completion of Series A Financing for Eleventh Company
Devices Venture Capital Personnel
 HSMN NewsFeed - 14 Dec 2008
FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Nov 2008
David R. King Joins Diasome Pharmaceuticals as Chairman of the Board
Biopharmaceuticals Endocrinology Drug Delivery Personnel
 HSMN NewsFeed - 31 Jul 2008
Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Jul 2008
Eisai Receives Action Letter on Fospropofol Disodium Injection for Sedation in Diagnostic or Therapeutic Procedures
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Jul 2008
Agios Pharmaceuticals Closes $33 Million Series A Funding
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 1 Jul 2008
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jun 2008
Industry Veteran David R. King Joins Quaker BioVentures
Venture Capital
 HSMN NewsFeed - 20 May 2008
Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 May 2008
Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Apr 2008
Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Apr 2008
European Regulatory Agency Grants Orphan Status to Morphotek(R)'s Farletuzumab and MORAb-009
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Mar 2008
Morphotek(R) Signs Exclusive Licensing Agreement for Anti-Cancer Antibody
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Mar 2008
FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jan 2008
Eisai Completes Acquisition of MGI PHARMA
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 17 Jan 2008
Eisai and MGI PHARMA Announce Early Termination of HSR Waiting Period for Eisai's Acquisition of MGI PHARMA
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Dec 2007
Eisai to Acquire MGI PHARMA for $41 Per Share in an All Cash Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Nov 2007
BIND Biosciences, Inc. Closes $16M Series B Financing Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 19 Oct 2007
TransMolecular, Inc. Names Morphotek Executive Nicholas C. Nicolaides, Ph.D., Chairman of the Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Oct 2007
ForSight Labs Announces Acquisition of ForSight Newco II by QLT, Inc.
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 23 Aug 2007
Prestwick Pharmaceuticals, Inc. Strengthens Management Team with Appointment of Robert S. Radie as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Apr 2007
Eisai Announces Completion of Acquisition of Morphotek
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Mar 2007
Eisai To Acquire Morphotek
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Feb 2007
Morphotek Obtains Exclusive License from Micromet for Antibody to Treat Melanoma and Other Cancers
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Nov 2006
Monoclonal Antibody, MORAb-009, Receives FDA Orphan Drug Designation for the Indication of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Oct 2006
Morphotek Raises $40 Million to Advance Its Antibody Pipeline
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 Jun 2006
Morphotek Announces Orphan Drug Status Granted for MORAb-003, A Monoclonal Antibody for the Treatment of Ovarian Cancer
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 6

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 6 additional stories matching:
Morphotek
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.